aspects of adverse effects

Patient suffers side effect in Cabaletta autoimmune CAR-T trial, but analysts unfazed

3 weeks ago talkbio0Tagged Adverse effects, analysts, aspects of adverse effects, Autoimmune Diseases, Cabaletta, CAR-T therapy, cell-associated neurotoxicity, Cytokine Release Syndrome, Lupus Erythematosus, Systemic, reSET (device), Systemic Scleroderma

Systemic Scleroderma, Lupus Erythematosus, Systemic, Cabaletta, cell-associated neurotoxicity, Adverse effects, analysts, Autoimmune Diseases, CAR-T therapy, reSET (device), aspects of adverse effects, Cytokine Release Syndrome

GLP-1 Medications: Balancing Efficacy and Concerns Amidst Celebrity Endorsements and Rising Demand

4 months ago talkbio0Tagged agonists, aspects of adverse effects, Diabetes Mellitus, Non-Insulin-Dependent, Employer, Endorsements, Famous Persons, Financial cost, Glucagon-Like Peptide 1, Health Planning, Long-term Safety, Weight Loss

GLP-1 agonists, Weight loss, Type 2 diabetes, Celebrity endorsements, Side effects, Long-term safety, Cost implications, Employer health plans

Roche’s Obesity Pill Candidate Faces Safety Concerns Amid Promising Efficacy Results

7 months ago talkbio0Tagged aspects of adverse effects, concerns, Contraceptives, Oral, CT-996, Effectiveness, Gastrointestinal Issues, Nausea, Obesity, Roche (company), Safety, Vomiting

Roche, Obesity Pill, Safety Concerns, Efficacy Data, CT-996, Side Effects, Nausea, Vomiting, Gastrointestinal Issues

FDA Approves Updated Covid Vaccines for Fall Season: What You Need to Know

8 months ago talkbio0Tagged Approved, aspects of adverse effects, COVID19 (disease), fall season, Immune response, KP.2, Muscle strain, Timing, United States Food and Drug Administration, Vaccination, Vaccines

Covid-19 vaccines, FDA approval, updated vaccines, fall season, KP.2 strain, vaccination timing, immunity, side effects.

EU Regulatory Panel Rejects Eisai and Biogen’s Leqembi for Alzheimer’s Treatment

9 months ago talkbio0Tagged Agencies, Alzheimer 's disease, approval rejection, aspects of adverse effects, Biogen, Eisai, European (ethnic group), Leqembi, regulatory panel

Leqembi, Alzheimer’s disease, Eisai, Biogen, European Medicines Agency, regulatory panel, approval rejection, adverse effects

Tango Pauses Clinical Trials of Promising Solid Tumor Treatment Due to Liver Toxicity Concerns

11 months ago talkbio0Tagged ARNT gene, aspects of adverse effects, Cancer Research, Clinical Trials, Drug Development, Liver, solid tumor treatment, Toxicity aspects

Tango Therapeutics, solid tumor treatment, clinical trials, liver toxicity, drug development, cancer research, treatment side effects, patient safety.

FDA Greenlights Idorsia’s Aprocitentan (Tryvio) for Resistant Hypertension Patients

1 year ago talkbio0Tagged 12.5 mg, Approved, aprocitentan, aspects of adverse effects, Availability of, Clinical Trials, Combined Modality Therapy, Edema, Endothelin receptor antagonist, Idorsia, Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative, Liquid substance, Precision - temporal, Recommended dosage, Resistant hypertensive disorder, Retention (Psychology), Second Half of 2024, Tryvio, Uncontrolled hypertension, United States Food and Drug Administration

FDA approval, Idorsia, Aprocitentan, Tryvio, Resistant hypertension, Endothelin receptor antagonist, Systolic blood pressure, Uncontrolled hypertension, Combination therapy, Clinical trials, PRECISION study, Recommended dosage: 12.5 mg, Availability: Second half of 2024, Edema and fluid retention side effects

FDA Unexpectedly Postpones Approval Decision for Eli Lilly’s Donanemab, Schedules AdComm Review

1 year ago talkbio0Tagged Accelerated Approval, Aduhelm, Anticipated, Approved, aspects of adverse effects, Central Nervous System Agents, Cerebral Edema, Clinical Trials, Deferred, Donanemab, Effectiveness, eli lilly, Full approval, Hemorrhage, Leqembi, PCNS, Peripheral, precedent, Review [Publication Type], Safety, United States Food and Drug Administration

Donanemab, Eli Lilly, FDA delay, Approval postponement, Peripheral and Central Nervous System Drugs Advisory Committee (PCNS), Safety and efficacy review, Clinical trial results, Brain swelling and bleeding side effects, Accelerated approval declined, Leqembi and Aduhelm precedent, Full approval anticipated, Accelerated approval rejected.

Promising Vertex Pain Med Points to New Era for Analgesics

1 year ago talkbio0Tagged Analgesics, Analgesics, Opioid, aspects of adverse effects, Effectiveness, historical period, VX-548

historical period, Analgesics, Opioid, VX-548, Analgesics, Effectiveness, aspects of adverse effects